U.S. markets closed
  • S&P Futures

    3,293.75
    +30.25 (+0.93%)
     
  • Dow Futures

    26,654.00
    +245.00 (+0.93%)
     
  • Nasdaq Futures

    11,233.25
    +100.50 (+0.90%)
     
  • Russell 2000 Futures

    1,550.80
    +11.60 (+0.75%)
     
  • Crude Oil

    37.36
    -0.03 (-0.08%)
     
  • Gold

    1,879.40
    +0.20 (+0.01%)
     
  • Silver

    23.44
    +0.08 (+0.35%)
     
  • EUR/USD

    1.1755
    +0.0006 (+0.05%)
     
  • 10-Yr Bond

    0.7810
    +0.0030 (+0.39%)
     
  • Vix

    40.28
    +6.93 (+20.78%)
     
  • GBP/USD

    1.2998
    +0.0011 (+0.08%)
     
  • USD/JPY

    104.4740
    +0.1730 (+0.17%)
     
  • BTC-USD

    13,210.58
    -6.71 (-0.05%)
     
  • CMC Crypto 200

    261.48
    -11.21 (-4.11%)
     
  • FTSE 100

    5,582.80
    -146.19 (-2.55%)
     
  • Nikkei 225

    23,261.98
    -156.53 (-0.67%)
     

We Think Nektar Therapeutics (NASDAQ:NKTR) Can Afford To Drive Business Growth

Simply Wall St
·4 mins read

Just because a business does not make any money, does not mean that the stock will go down. For example, although Amazon.com made losses for many years after listing, if you had bought and held the shares since 1999, you would have made a fortune. Having said that, unprofitable companies are risky because they could potentially burn through all their cash and become distressed.

So should Nektar Therapeutics (NASDAQ:NKTR) shareholders be worried about its cash burn? For the purpose of this article, we'll define cash burn as the amount of cash the company is spending each year to fund its growth (also called its negative free cash flow). Let's start with an examination of the business' cash, relative to its cash burn.

Check out our latest analysis for Nektar Therapeutics

Does Nektar Therapeutics Have A Long Cash Runway?

A company's cash runway is calculated by dividing its cash hoard by its cash burn. When Nektar Therapeutics last reported its balance sheet in June 2020, it had zero debt and cash worth US$1.0b. Looking at the last year, the company burnt through US$368m. So it had a cash runway of about 2.8 years from June 2020. Notably, analysts forecast that Nektar Therapeutics will break even (at a free cash flow level) in about 4 years. Essentially, that means the company will either reduce its cash burn, or else require more cash. The image below shows how its cash balance has been changing over the last few years.

debt-equity-history-analysis
debt-equity-history-analysis

How Well Is Nektar Therapeutics Growing?

Some investors might find it troubling that Nektar Therapeutics is actually increasing its cash burn, which is up 4.8% in the last year. The silver lining is that revenue was up 36%, showing the business is growing at the top line. On balance, we'd say the company is improving over time. While the past is always worth studying, it is the future that matters most of all. For that reason, it makes a lot of sense to take a look at our analyst forecasts for the company.

How Easily Can Nektar Therapeutics Raise Cash?

While Nektar Therapeutics seems to be in a decent position, we reckon it is still worth thinking about how easily it could raise more cash, if that proved desirable. Generally speaking, a listed business can raise new cash through issuing shares or taking on debt. One of the main advantages held by publicly listed companies is that they can sell shares to investors to raise cash and fund growth. By looking at a company's cash burn relative to its market capitalisation, we gain insight on how much shareholders would be diluted if the company needed to raise enough cash to cover another year's cash burn.

Nektar Therapeutics' cash burn of US$368m is about 13% of its US$2.9b market capitalisation. As a result, we'd venture that the company could raise more cash for growth without much trouble, albeit at the cost of some dilution.

How Risky Is Nektar Therapeutics' Cash Burn Situation?

It may already be apparent to you that we're relatively comfortable with the way Nektar Therapeutics is burning through its cash. For example, we think its cash runway suggests that the company is on a good path. Although its increasing cash burn does give us reason for pause, the other metrics we discussed in this article form a positive picture overall. Shareholders can take heart from the fact that analysts are forecasting it will reach breakeven. Considering all the factors discussed in this article, we're not overly concerned about the company's cash burn, although we do think shareholders should keep an eye on how it develops. Its important for readers to be cognizant of the risks that can affect the company's operations, and we've picked out 4 warning signs for Nektar Therapeutics that investors should know when investing in the stock.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies insiders are buying, and this list of stocks growth stocks (according to analyst forecasts)

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.